Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07830329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Name: Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity — clinical trial record (NCT07830329)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorRegeneron Pharmaceuticals

Started2026-10-30

View on ClinicalTrials.gov ↗

Regeneron

148 trials monitored

See 16 trials at risk

Hidradenitis Suppurativa

134 trials monitored

See 4 trials at risk

This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss. The study is looking at: * What side effects olatorepatide might cause * How well olatorepatide works * How much olatorepatide is in the blood at different times * If the body makes antibodies to olatorepatide, which may cause olatorepatide to not work as well

Trial Details

NCT Number	NCT07830329
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Hidradenitis Suppurativa
Enrollment	300 participants
Start Date	2026-10-30
Primary Completion	2028-11-24 (estimated)
Study Completion	2028-12-22 (estimated)
Updated on ClinicalTrials.gov	2026-09-21